Fate Therapeutics Future Growth
Future criteria checks 0/6
Fate Therapeutics's earnings are forecast to decline at 7.7% per annum while its annual revenue is expected to grow at 3% per year. EPS is expected to grow by 0.8% per annum. Return on equity is forecast to be -70.2% in 3 years.
Key information
-7.7%
Earnings growth rate
0.8%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 3.0% |
Future return on equity | -70.2% |
Analyst coverage | Good |
Last updated | 19 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 6 | -252 | -150 | -57 | 5 |
12/31/2025 | 5 | -211 | -163 | -147 | 14 |
12/31/2024 | 5 | -195 | -139 | -155 | 17 |
12/31/2023 | 64 | -161 | -138 | -132 | N/A |
9/30/2023 | 106 | -173 | -184 | -171 | N/A |
6/30/2023 | 119 | -212 | -209 | -188 | N/A |
3/31/2023 | 137 | -235 | -241 | -212 | N/A |
12/31/2022 | 96 | -282 | -284 | -248 | N/A |
9/30/2022 | 69 | -294 | -290 | -243 | N/A |
6/30/2022 | 68 | -254 | -275 | -221 | N/A |
3/31/2022 | 63 | -233 | -257 | -200 | N/A |
12/31/2021 | 56 | -212 | -214 | -163 | N/A |
9/30/2021 | 55 | -197 | -148 | -113 | N/A |
6/30/2021 | 48 | -212 | -131 | -111 | N/A |
3/31/2021 | 40 | -185 | -47 | -40 | N/A |
12/31/2020 | 31 | -173 | -44 | -39 | N/A |
9/30/2020 | 18 | -149 | -49 | -44 | N/A |
6/30/2020 | 13 | -117 | -39 | -33 | N/A |
3/31/2020 | 11 | -112 | -99 | -92 | N/A |
12/31/2019 | 11 | -98 | -91 | -83 | N/A |
9/30/2019 | 10 | -86 | -75 | -69 | N/A |
6/30/2019 | 8 | -76 | -58 | -52 | N/A |
3/31/2019 | 6 | -72 | -47 | -44 | N/A |
12/31/2018 | 5 | -67 | -41 | -39 | N/A |
9/30/2018 | 4 | -63 | -40 | -38 | N/A |
6/30/2018 | 4 | -57 | -46 | -45 | N/A |
3/31/2018 | 4 | -47 | -44 | -42 | N/A |
12/31/2017 | 4 | -43 | -39 | -37 | N/A |
9/30/2017 | 4 | -38 | N/A | -34 | N/A |
6/30/2017 | 4 | -36 | N/A | -31 | N/A |
3/31/2017 | 4 | -35 | N/A | -30 | N/A |
12/31/2016 | 4 | -33 | N/A | -30 | N/A |
9/30/2016 | 4 | -33 | N/A | -29 | N/A |
6/30/2016 | 4 | -31 | N/A | -29 | N/A |
3/31/2016 | 4 | -30 | N/A | -19 | N/A |
12/31/2015 | 2 | -30 | N/A | -18 | N/A |
9/30/2015 | 1 | -29 | N/A | -18 | N/A |
6/30/2015 | 0 | -28 | N/A | -16 | N/A |
3/31/2015 | N/A | -27 | N/A | -24 | N/A |
12/31/2014 | N/A | -26 | N/A | -22 | N/A |
9/30/2014 | N/A | -25 | N/A | -21 | N/A |
6/30/2014 | 0 | -25 | N/A | -19 | N/A |
3/31/2014 | 0 | -24 | N/A | -17 | N/A |
12/31/2013 | 1 | -21 | N/A | -15 | N/A |
9/30/2013 | 2 | -19 | N/A | -14 | N/A |
6/30/2013 | 2 | -17 | N/A | -13 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: F6T is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: F6T is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: F6T is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: F6T's revenue (3% per year) is forecast to grow slower than the German market (5.5% per year).
High Growth Revenue: F6T's revenue (3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: F6T is forecast to be unprofitable in 3 years.